Unknown

Dataset Information

0

CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.


ABSTRACT: Immunotherapies with chimeric antigen receptor (CAR) T cells and checkpoint inhibitors (including antibodies that antagonize programmed cell death protein 1 [PD-1]) have both opened new avenues for cancer treatment, but the clinical potential of combined disruption of inhibitory checkpoints and CAR T cell therapy remains incompletely explored. Here we show that programmed death ligand 1 (PD-L1) expression on tumor cells can render human CAR T cells (anti-CD19 4-1BB?) hypo-functional, resulting in impaired tumor clearance in a sub-cutaneous xenograft model. To overcome this suppressed anti-tumor response, we developed a protocol for combined Cas9 ribonucleoprotein (Cas9 RNP)-mediated gene editing and lentiviral transduction to generate PD-1 deficient anti-CD19 CAR T cells. Pdcd1 (PD-1) disruption augmented CAR T cell mediated killing of tumor cells in vitro and enhanced clearance of PD-L1+ tumor xenografts in vivo. This study demonstrates improved therapeutic efficacy of Cas9-edited CAR T cells and highlights the potential of precision genome engineering to enhance next-generation cell therapies.

SUBMITTER: Rupp LJ 

PROVIDER: S-EPMC5428439 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.

Rupp Levi J LJ   Schumann Kathrin K   Roybal Kole T KT   Gate Rachel E RE   Ye Chun J CJ   Lim Wendell A WA   Marson Alexander A  

Scientific reports 20170407 1


Immunotherapies with chimeric antigen receptor (CAR) T cells and checkpoint inhibitors (including antibodies that antagonize programmed cell death protein 1 [PD-1]) have both opened new avenues for cancer treatment, but the clinical potential of combined disruption of inhibitory checkpoints and CAR T cell therapy remains incompletely explored. Here we show that programmed death ligand 1 (PD-L1) expression on tumor cells can render human CAR T cells (anti-CD19 4-1BBζ) hypo-functional, resulting i  ...[more]

Similar Datasets

| S-EPMC8627098 | biostudies-literature
| S-EPMC6174208 | biostudies-literature
| S-EPMC6287795 | biostudies-literature
2021-06-03 | GSE151774 | GEO
| S-EPMC5563282 | biostudies-literature
| S-EPMC6205063 | biostudies-literature
| S-EPMC7904846 | biostudies-literature
| S-EPMC6980372 | biostudies-literature
| S-EPMC7461863 | biostudies-literature
| S-EPMC10591343 | biostudies-literature